In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial

Fossat, C.; Juhan‐Vague, I.; Stoppa, Anne Marie; Sainty, Danielle; Blaise, Didier; Viens, Patrice; Maraninchi, D; Bayssasc, Martine; Yver, Antoine

doi:10.1002/stem.5530120308

Cited by 18 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, bactericidal activity and bacterial phagocytosis, as assessed by direct microscopy, were found to be significantly enhanced following pre‐incubation of normal PMN with G‐CSF ( Roilides et al , 1991 ). These results support the findings of a recent study investigating the in vivo stimulation of PMN function by G‐CSF in non‐neutropenic cancer patients ( Fossat et al , 1994 ). Circulating PMN from uraemic ESRF patients on CAPD show reduced phagocytosis and intercellular killing of S. epidermidis ( Harvey et al , 1987 , 1988).…”

Section: Discussionsupporting

confidence: 91%

Effects of r‐metHuG‐CSF on polymorphonuclear leucocyte kinetics and function in patients on continuous ambulatory peritoneal dialysis

Turzanski

Crouch²,

Andrews

et al. 1998

Br J Haematol

View full text Add to dashboard Cite

Summary. End-stage renal failure (ESRF) patients undergoing continuous ambulatory peritoneal dialysis (CAPD) are immunocompromised and exhibit abnormal circulating polymorphonuclear leucocyte (PMN) function, including reduced phagocytosis and intracellular killing. Six uraemic patients on CAPD were each given 300 mg granulocytecolony stimulating factor (G-CSF) every day for 5 d and PMN function tests were performed daily. By day 5 of the study CD11b expression was significantly decreased in response to N-formylmethionylleucylphenylalanine (fMLP) and opsonized Staphylococcus epidermidis stimulation, and expression of L-selectin (CD62L) was significantly decreased in response to opsonized Staphylococcus epidermidis stimulation. Further, superoxide anion production and FcgRI (CD64) expression were found to be significantly increased and FcgRIII (CD16) expression was lowered. Circulating white cell and PMN counts were significantly elevated in response to treatment. Administration of G-CSF did not appear to have corrected the abnormalities in phagocytosis and intracellular killing. This study suggests that G-CSF does no harm to ESRF patients and influences uraemic PMN function in a manner that is comparable to its effects on PMN in non-uraemic subjects.

show abstract

Section: Discussionsupporting

confidence: 91%

Effects of r‐metHuG‐CSF on polymorphonuclear leucocyte kinetics and function in patients on continuous ambulatory peritoneal dialysis

Turzanski

Crouch²,

Andrews

et al. 1998

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…There is evidence for differences between these three G‐CSF formulations in modifying neutrophil functions. Generally, chemotactic properties, which are essential for granulocyte function in host defense, are known to be impaired after treatment with G‐CSF 8‐12 . Azzara and coworkers 13 observed that filgrastim reduced chemotaxis more than lenograstim; recently published data attribute this reduced chemotaxis as well as morphological changes after filgrastim to cytoskeletal rearrangements 14 .…”

mentioning

confidence: 99%

Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim

Ribeiro¹,

Veldwijk²,

Benner

et al. 2007

Transfusion

View full text Add to dashboard Cite

show abstract

“…Bacterial phagocytosis and bactericidal activity against Staphylococcus aureus have been found to be significantly enhanced after preincubation of normal PMN with G-CSF (Roilides et al, 1991). In addition, G-CSF has recently been reported to enhance the phagocytosis and bacterial killing of Staphylococcus aureus in non-neutropenic cancer patients (Fossat et al, 1994).…”

mentioning

confidence: 99%

Ex vivo neutrophil function in response to three different doses of glycosylated rHuG‐CSF (Lenograstim)

Turzanski¹,

Crouch²,

Fletcher³

et al. 1997

Br J Haematol

View full text Add to dashboard Cite

Summary. Granulocyte colony-stimulating factor (G-CSF) is being considered as adjuvant treatment for infections in non-neutropenic patients. Normal healthy donors were given rHuG-CSF (Lenograstim) at 2 . 5, 5 . 0 and 7 . 5 g/kg subcutaneously daily for 5 d. Polymorphonuclear leucocyte (PMN) function tests were carried out on peripheral blood PMN before the first injection and at 24 h and 96 h. Circulating PMN levels were also measured at these time intervals and found to be significantly increased with all doses by 24 and 96 h. Investigation of cell surface antigen expression revealed no changes in 2 integrin (CD11b/ CD18) expression. L-selectin (CD62L) expression was reduced with all doses by 96 h, this being significant with the 7 . 5 g/kg dose. FcRI (CD64) levels were significantly up-regulated with the 7 . 5 g/kg dose by 96 h whereas FcRIII (CD16) expression was found to be reduced during G-CSF treatment. Superoxide anion production was significantly increased in response to N-formylmethionylleucylphenylalanine (FMLP) and opsonized Staphylococcus epidermidis stimulation at 24 h and 96 h with the 5 . 0 and 7 . 5 g/kg doses. The initial rate of phagocytosis (0-2 min) appeared to have increased with the 7 . 5 and 5 . 0 g/kg doses at 96 and 24 h compared with PMN responses pretreatment, although these increases were not statistically significant. These results show that G-CSF enhances the functional responses of PMN stimulated by physiological agonists and may help in the treatment of infections.

show abstract

In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial

Abstract: Abstract. The aim of this work was to study the evolution of neutrophil functions in non-neutropenic cancer patients. Thirty non-neutropenic patients, median age 35 years (range 19-52), with solid tumors (n = 21) or lymphomas (n = 9) entered a phase

Cited by 18 publications

References 26 publications

Effects of r‐metHuG‐CSF on polymorphonuclear leucocyte kinetics and function in patients on continuous ambulatory peritoneal dialysis

Effects of r‐metHuG‐CSF on polymorphonuclear leucocyte kinetics and function in patients on continuous ambulatory peritoneal dialysis

Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim

Ex vivo neutrophil function in response to three different doses of glycosylated rHuG‐CSF (Lenograstim)

Contact Info

Product

Resources

About